{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:38:29Z","timestamp":1791315509665,"version":"4.3.1"},"reference-count":220,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>The primary node molecules in the cell signaling network in cancer tissues are maladjusted and mutated in comparison to normal tissues, which promotes the occurrence and progression of cancer. Pancreatic cancer (PC) is a highly fatal cancer with increasing incidence and low five-year survival rates. Currently, there are several therapies that target cell signaling networks in PC. However, PC is a \u201ccold tumor\u201d with a unique immunosuppressive tumor microenvironment (poor effector T cell infiltration, low antigen specificity), and targeting a single gene or pathway is basically ineffective in clinical practice. Targeted matrix therapy, targeted metabolic therapy, targeted mutant gene therapy, immunosuppressive therapy, cancer vaccines, and other emerging therapies have shown great therapeutic potential, but results have been disappointing. Therefore, we summarize the identified and potential drug-resistant cell signaling networks aimed at overcoming barriers to existing PC therapies.<\/jats:p>","DOI":"10.3389\/fcell.2024.1462808","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T06:13:04Z","timestamp":1736748784000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["A stumbling block in pancreatic cancer treatment: drug resistance signaling networks"],"prefix":"10.3389","volume":"12","author":[{"given":"Jinming","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3389\/fimmu.2018.02166","article-title":"The potential of CAR T cell therapy in pancreatic cancer","volume":"9","author":"Akce","year":"2018","journal-title":"Front. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/2159-8290.CD-20-1616","article-title":"Mechanisms of resistance to KRAS(G12C)-Targeted therapy","volume":"11","author":"Akhave","year":"2021","journal-title":"Cancer Discov."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2080329","DOI":"10.1080\/2162402X.2022.2080329","article-title":"MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy","volume":"11","author":"Baleeiro","year":"2022","journal-title":"Oncoimmunology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10555-021-09990-2","article-title":"Targeting KRAS in pancreatic cancer: new drugs on the horizon","volume":"40","author":"Bannoura","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic cancer immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bbcan.2018.04.011","article-title":"The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance","volume":"1870","author":"Biancur","year":"2018","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41577-023-00898-2","article-title":"Combining EZH2 inhibition with senescence induction helps immune cells fight pancreatic cancer","volume":"23","author":"Bordon","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"102614","DOI":"10.1016\/j.ctrv.2023.102614","article-title":"Novel targets for immune-checkpoint inhibition in cancer","volume":"120","author":"Borgeaud","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/nchembio.2143","article-title":"Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition","volume":"12","author":"Boudreau","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"11133","DOI":"10.1038\/s41598-020-67814-9","article-title":"Beta 1 integrin signaling mediates pancreatic ductal adenocarcinoma resistance to MEK inhibition","volume":"10","author":"Brannon","year":"2020","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"B14","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-019-0368-8","article-title":"Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer","volume":"25","author":"Bryant","year":"2019","journal-title":"Nat. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/s0198-8859(03)00164-2","article-title":"High frequency of HLA-B44 allelic losses in human solid tumors","volume":"64","author":"Cabrera","year":"2003","journal-title":"Hum. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.semcancer.2019.07.007","article-title":"Revisiting the hallmarks of cancer: the role of hyaluronan","volume":"62","author":"Caon","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1002\/1878-0261.13042","article-title":"Overcoming the senescence-associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer","volume":"15","author":"Chambers","year":"2021","journal-title":"Mol. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"7950","DOI":"10.1038\/s41598-017-08436-6","article-title":"Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"8692","DOI":"10.7150\/thno.60437","article-title":"Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis","volume":"11","author":"Chen","year":"2021","journal-title":"Theranostics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.apsb.2022.11.013","article-title":"An mRNA vaccine elicits STING-dependent antitumor immune responses","volume":"13","author":"Chen","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9162","DOI":"10.1038\/s41598-020-65804-5","article-title":"PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin \u03b23-KRAS-dependent pancreatic cancer stem cells","volume":"10","author":"Cheng","year":"2020","journal-title":"Sci. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s43018-023-00553-8","article-title":"EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance","volume":"4","author":"Chibaya","year":"2023","journal-title":"Nat. Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.semcancer.2022.02.005","article-title":"Senescence and the tumor-immune landscape: implications for cancer immunotherapy","volume":"86","author":"Chibaya","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1136\/gutjnl-2017-315144","article-title":"Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer","volume":"67","author":"Chou","year":"2018","journal-title":"Gut"},{"key":"B25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1083\/jcb.200304132","article-title":"Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels","volume":"163","author":"Christian","year":"2003","journal-title":"J. Cell Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/cancers9050042","article-title":"KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer","volume":"9","author":"Cicenas","year":"2017","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2345940","DOI":"10.1080\/21645515.2024.2345940","article-title":"Exosome may be the next generation of promising cell-free vaccines","volume":"20","author":"Dai","year":"2024","journal-title":"Hum. Vaccin Immunother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1158\/0008-5472.CAN-19-0960","article-title":"Deoxycytidine release from pancreatic stellate cells promotes gemcitabine resistance","volume":"79","author":"Dalin","year":"2019","journal-title":"Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-10-1855","article-title":"Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2","volume":"71","author":"Dangi-Garimella","year":"2011","journal-title":"Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e64566","DOI":"10.1371\/journal.pone.0064566","article-title":"Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression","volume":"8","author":"Dangi-Garimella","year":"2013","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ccr.2014.06.004","article-title":"Response to Chauhan et Al.: interstitial pressure and vascular collapse in pancreas cancer-fluids and solids, measurement and meaning","volume":"26","author":"DelGiorno","year":"2014","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/ng1001-117","article-title":"TGF-beta signaling in tumor suppression and cancer progression","volume":"29","author":"Derynck","year":"2001","journal-title":"Nat. Genet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature21052","article-title":"Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer","volume":"542","author":"Dey","year":"2017","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0143755","DOI":"10.1371\/journal.pone.0143755","article-title":"MicroRNA profiling implies new markers of gemcitabine chemoresistance in mutant p53 pancreatic ductal adenocarcinoma","volume":"10","author":"Dhayat","year":"2015","journal-title":"PLoS One"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1186\/s12885-019-6145-8","article-title":"IFN-gamma down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer","volume":"19","author":"Ding","year":"2019","journal-title":"BMC Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3390\/cancers13061302","article-title":"Agonistic CD40 antibodies in cancer treatment","volume":"13","author":"Djureinovic","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.semcancer.2017.10.007","article-title":"KRAS, YAP, and obesity in pancreatic cancer: a signaling network with multiple loops","volume":"54","author":"Eibl","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.molimm.2013.11.020","article-title":"Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes","volume":"58","author":"El-Jawhari","year":"2014","journal-title":"Mol. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s43018-023-00647-3","article-title":"Targeting pancreatic cancer metabolic dependencies through glutamine antagonism","volume":"5","author":"Encarnaci\u00f3n-Rosado","year":"2024","journal-title":"Nat. Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"10646","DOI":"10.1039\/d1ra00855b","article-title":"Employing hydrogels in tissue engineering approaches to boost conventional cancer-based research and therapies","volume":"11","author":"Esmaeili","year":"2021","journal-title":"RSC Adv."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1038\/s41388-021-01726-4","article-title":"SMAD4 loss limits the vulnerability of pancreatic cancer cells to complex I inhibition via promotion of mitophagy","volume":"40","author":"Ezrova","year":"2021","journal-title":"Oncogene"},{"key":"B42","doi-asserted-by":"publisher","first-page":"5903","DOI":"10.1002\/cam4.2463","article-title":"Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer","volume":"8","author":"Fan","year":"2019","journal-title":"Cancer Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1053\/j.gastro.2020.09.010","article-title":"Mesenchymal plasticity regulated by Prrx1 drives aggressive pancreatic cancer biology","volume":"160","author":"Feldmann","year":"2021","journal-title":"Gastroenterology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13046-018-0947-4","article-title":"LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer","volume":"37","author":"Feng","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.3390\/cancers13174442","article-title":"The extracellular matrix in pancreatic cancer: description of a complex network and promising therapeutic options","volume":"13","author":"Ferrara","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bbamcr.2014.10.003","article-title":"Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine","volume":"1853","author":"Fiorini","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"B47","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/path.5154","article-title":"From somatic mutation to early detection: insights from molecular characterization of pancreatic cancer precursor lesions","volume":"246","author":"Fischer","year":"2018","journal-title":"J. Pathol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"10060","DOI":"10.1038\/s41598-017-09946-z","article-title":"ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer","volume":"7","author":"Gharibi","year":"2017","journal-title":"Sci. Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"7181","DOI":"10.1158\/0008-5472.CAN-16-0300","article-title":"Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature","volume":"76","author":"Gilles","year":"2016","journal-title":"Cancer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.3390\/cancers14143528","article-title":"Autophagy: a key player in pancreatic cancer progression and a potential drug target","volume":"14","author":"Gillson","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2015.09.012","article-title":"Tumor-extracellular matrix interactions: identification of tools associated with breast cancer progression","volume":"35","author":"Giussani","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1136\/gutjnl-2018-317570","article-title":"Stromal protein \u03b2ig-h3 reprogrammes tumour microenvironment in pancreatic cancer","volume":"68","author":"Goehrig","year":"2019","journal-title":"Gut"},{"key":"B53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/0008-5472.CAN-22-0391","article-title":"Combination therapies with CDK4\/6 inhibitors to treat KRAS-mutant pancreatic cancer","volume":"83","author":"Goodwin","year":"2023","journal-title":"Cancer Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.critrevonc.2017.03.026","article-title":"Drug resistance in pancreatic cancer: impact of altered energy metabolism","volume":"114","author":"Grasso","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1259\/0007-1285-26-312-638","article-title":"The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy","volume":"26","author":"Gray","year":"1953","journal-title":"Br. J. Radiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3390\/cancers15030628","article-title":"Prognostic significance of integrin subunit alpha 2 (ITGA2) and role of mechanical cues in resistance to gemcitabine in pancreatic ductal adenocarcinoma (PDAC)","volume":"15","author":"Gregori","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"46714","DOI":"10.1038\/srep46714","article-title":"Ionizing radiation abrogates the pro-tumorigenic capacity of cancer-associated fibroblasts co-implanted in xenografts","volume":"7","author":"Grinde","year":"2017","journal-title":"Sci. Rep."},{"key":"B58","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41420-023-01306-3","article-title":"Cancer-associated fibroblasts induce growth and radioresistance of breast cancer cells through paracrine IL-6","volume":"9","author":"Guo","year":"2023","journal-title":"Cell Death Discov."},{"key":"B59","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1158\/0008-5472.CAN-22-2245","article-title":"Systematic interrogation of tumor cell resistance to chimeric antigen receptor T-cell therapy in pancreatic cancer","volume":"83","author":"Hagel","year":"2023","journal-title":"Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ccell.2016.12.006","article-title":"Employing metabolism to improve the diagnosis and treatment of pancreatic cancer","volume":"31","author":"Halbrook","year":"2017","journal-title":"Cancer Cell"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.cmet.2019.02.001","article-title":"Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer","volume":"29","author":"Halbrook","year":"2019","journal-title":"Cell Metab."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1158\/1078-0432.CCR-13-2972","article-title":"Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer","volume":"20","author":"Hartmann","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41575-021-00463-z","article-title":"The pancreatic cancer genome revisited","volume":"18","author":"Hayashi","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/carcin\/bgw093","article-title":"TGF-\u03b2-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3","volume":"37","author":"Hesler","year":"2016","journal-title":"Carcinogenesis"},{"key":"B65","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1136\/gutjnl-2016-311954","article-title":"Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer","volume":"67","author":"Hessmann","year":"2018","journal-title":"Gut"},{"key":"B66","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/SLA.0000000000004669","article-title":"A phase 3 randomized clinical trial of chemotherapy with or without algenpantucel-L (HyperAcute-Pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer","volume":"275","author":"Hewitt","year":"2022","journal-title":"Ann. Surg."},{"key":"B67","doi-asserted-by":"publisher","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"key":"B68","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/sj.bjp.0701795","article-title":"Differential mechanism for the cell surface sorting and agonist-promoted internalization of the alpha1B-adrenoceptor","volume":"124","author":"Hirasawa","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"40215","DOI":"10.1074\/jbc.M101647200","article-title":"MMP inhibitors augment fibroblast adhesion through stabilization of focal adhesion contacts and up-regulation of cadherin function","volume":"276","author":"Ho","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B70","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/2159-8290.Cd-19-1006","article-title":"Atypical KRAS(G12R) mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer","volume":"10","author":"Hobbs","year":"2020","journal-title":"Cancer Discov."},{"key":"B72","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/cac2.12459","article-title":"Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer","volume":"43","author":"Hu","year":"2023","journal-title":"Cancer Commun. (Lond)"},{"key":"B74","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat. Med."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673293445240409060446","article-title":"The molecular characteristics and therapeutic implications of O-glycan synthesis in pancreatic cancer by integrating transcriptome and single-cell data","volume":"31","author":"Huang","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"B76","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"","journal-title":"Signal Transduct. Target Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3892\/ijmm.2022.5184","article-title":"CDK4\/6 inhibitor resistance mechanisms and treatment strategies (Review)","volume":"50","author":"Huang","year":"","journal-title":"Int. J. Mol. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"","journal-title":"Signal Transduct. Target Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40779-022-00416-w","article-title":"Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine","volume":"9","author":"Huang","year":"","journal-title":"Mil. Med. Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B81","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.addr.2015.12.017","article-title":"The extracellular matrix in breast cancer","volume":"97","author":"Insua-Rodriguez","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B82","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","article-title":"Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer","volume":"62","author":"Jacobetz","year":"2013","journal-title":"Gut"},{"key":"B83","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/gutjnl-2018-317424","article-title":"Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion","volume":"69","author":"Jiang","year":"2020","journal-title":"Gut"},{"key":"B86","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/nrc2728","article-title":"p53-a Jack of all trades but master of none","volume":"9","author":"Junttila","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.devcel.2019.03.026","article-title":"The extracellular matrix modulates the metastatic journey","volume":"49","author":"Kai","year":"2019","journal-title":"Dev. Cell"},{"key":"B88","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41580-022-00531-5","article-title":"Organization, dynamics and mechanoregulation of integrin-mediated cell-ECM adhesions","volume":"24","author":"Kanchanawong","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10555-020-09952-0","article-title":"An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression","volume":"40","author":"Khan","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"B91","doi-asserted-by":"publisher","first-page":"8413","DOI":"10.1074\/jbc.RA119.011748","article-title":"Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer","volume":"295","author":"Khan","year":"2020","journal-title":"J. Biol. Chem."},{"key":"B92","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.1038\/onc.2010.230","article-title":"L1CAM-integrin interaction induces constitutive NF-kappaB activation in pancreatic adenocarcinoma cells by enhancing IL-1beta expression","volume":"29","author":"Kiefel","year":"2010","journal-title":"Oncogene"},{"key":"B93","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yexcr.2015.05.017","article-title":"Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells","volume":"336","author":"Kim","year":"2015","journal-title":"Exp. Cell Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"126","DOI":"10.5483\/bmbrep.2018.51.3.015","article-title":"DNA binding partners of YAP\/TAZ","volume":"51","author":"Kim","year":"2018","journal-title":"BMB Rep."},{"key":"B95","doi-asserted-by":"publisher","first-page":"e62645","DOI":"10.7554\/eLife.62645","article-title":"Hyaluronic acid fuels pancreatic cancer cell growth","volume":"10","author":"Kim","year":"2021","journal-title":"Elife"},{"key":"B96","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-019-0367-9","article-title":"Protective autophagy elicited by RAF\u2192MEK\u2192ERK inhibition suggests a treatment strategy for RAS-driven cancers","volume":"25","author":"Kinsey","year":"2019","journal-title":"Nat. Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","article-title":"KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and Adagrasib, and overcoming strategies: insights from in vitro experiments","volume":"16","author":"Koga","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","article-title":"LRRC15(+) myofibroblasts dictate the stromal setpoint to suppress tumour immunity","volume":"611","author":"Krishnamurty","year":"2022","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nm.4082","article-title":"Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression","volume":"22","author":"Laklai","year":"2016","journal-title":"Nat. Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1158\/2159-8290.CD-22-0192","article-title":"Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade","volume":"12","author":"Lander","year":"2022","journal-title":"Cancer Discov."},{"key":"B101","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1007\/s00018-021-03781-2","article-title":"Context-dependent roles of YAP\/TAZ in stem cell fates and cancer","volume":"78","author":"LeBlanc","year":"2021","journal-title":"Cell Mol. Life Sci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2019.02.043","article-title":"WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer","volume":"451","author":"Li","year":"","journal-title":"Cancer Lett."},{"key":"B103","first-page":"2192","article-title":"Radiation promotes epithelial-to-mesenchymal transition and invasion of pancreatic cancer cell by activating carcinoma-associated fibroblasts","volume":"6","author":"Li","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10456-018-9645-2","article-title":"Angiogenesis in pancreatic cancer: current research status and clinical implications","volume":"22","author":"Li","year":"","journal-title":"Angiogenesis"},{"key":"B105","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jconrel.2019.01.014","article-title":"KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs","volume":"296","author":"Liu","year":"","journal-title":"J. Control Release"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-023-01972-3","article-title":"Identification of novel biomarkers based on lipid metabolism-related molecular subtypes for moderately severe and severe acute pancreatitis","volume":"23","author":"Liu","year":"","journal-title":"Lipids Health Dis."},{"key":"B107","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1053\/j.gastro.2019.10.038","article-title":"ZIP4 increases expression of transcription factor ZEB1 to promote integrin alpha3beta1 signaling and inhibit expression of the gemcitabine transporter ENT1 in pancreatic cancer cells","volume":"158","author":"Liu","year":"2020","journal-title":"Gastroenterology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fcell.2019.00060","article-title":"Cancer-associated fibroblasts build and secure the tumor microenvironment","volume":"7","author":"Liu","year":"","journal-title":"Front. Cell Dev. Biol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"9837","DOI":"10.1074\/jbc.C600001200","article-title":"Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function","volume":"281","author":"Liu","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B110","doi-asserted-by":"publisher","first-page":"216640","DOI":"10.1016\/j.canlet.2024.216640","article-title":"CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy","volume":"585","author":"Liu","year":"","journal-title":"Cancer Lett."},{"key":"B111","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen quality predicts immunoediting in survivors of pancreatic cancer","volume":"606","author":"Luksza","year":"2022","journal-title":"Nature"},{"key":"B112","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","article-title":"Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation","volume":"2","author":"Lutz","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/mc.23719","article-title":"ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway","volume":"63","author":"Ma","year":"2024","journal-title":"Mol. Carcinog."},{"key":"B114","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"B115","doi-asserted-by":"publisher","first-page":"e1004262","DOI":"10.1371\/journal.pgen.1004262","article-title":"FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells","volume":"10","author":"Macagno","year":"2014","journal-title":"PLoS Genet."},{"key":"B116","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/JCI36308","article-title":"Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models","volume":"119","author":"Maione","year":"2009","journal-title":"J. Clin. Invest."},{"key":"B117","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"key":"B118","doi-asserted-by":"publisher","first-page":"100143","DOI":"10.1016\/j.xcrm.2020.100143","article-title":"Targeting mitochondrial complex I overcomes chemoresistance in high OXPHOS pancreatic cancer","volume":"1","author":"Masoud","year":"2020","journal-title":"Cell Rep. Med."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1080\/14737140.2018.1531707","article-title":"Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies","volume":"18","author":"Matsui","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B120","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/21645515.2015.1093264","article-title":"Pancreatic cancer: update on immunotherapies and algenpantucel-L","volume":"12","author":"McCormick","year":"2016","journal-title":"Hum. Vaccin Immunother."},{"key":"B121","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1158\/1078-0432.CCR-22-0784","article-title":"The crossroads of cancer epigenetics and immune checkpoint therapy","volume":"29","author":"Micevic","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B123","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1073\/pnas.0908428107","article-title":"Mutant p53 drives metastasis and overcomes growth arrest\/senescence in pancreatic cancer","volume":"107","author":"Morton","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B124","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3390\/cells10030662","article-title":"Collagen assembly at the cell surface: dogmas revisited","volume":"10","author":"Musiime","year":"2021","journal-title":"Cells"},{"key":"B125","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.hbpd.2018.09.004","article-title":"Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer","volume":"17","author":"Neumann","year":"2018","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"B126","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2022.01.004","article-title":"Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer","volume":"40","author":"Nicolas","year":"2022","journal-title":"Cancer Cell"},{"key":"B127","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/ijms23010146","article-title":"Matrix metalloproteinases shape the tumor microenvironment in cancer progression","volume":"23","author":"Niland","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3390\/cancers12051347","article-title":"Pancreatic cancer associated fibroblasts (CAF): under-explored target for pancreatic cancer treatment","volume":"12","author":"Norton","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"B130","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00262-022-03237-x","article-title":"Personalized tumor vaccine for pancreatic cancer","volume":"72","author":"Orr","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"B131","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd.2016.139","article-title":"Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design","volume":"15","author":"Ostrem","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","article-title":"Targeting integrin pathways: mechanisms and advances in therapy","volume":"8","author":"Pang","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"B133","doi-asserted-by":"publisher","first-page":"e56423","DOI":"10.1371\/journal.pone.0056423","article-title":"Human concentrative nucleoside transporter 3 transfection with ultrasound and microbubbles in nucleoside transport deficient HEK293 cells greatly increases gemcitabine uptake","volume":"8","author":"Paproski","year":"2013","journal-title":"PLoS One"},{"key":"B134","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B135","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fonc.2015.00288","article-title":"Targeting oncogenic mutant p53 for cancer therapy","volume":"5","author":"Parrales","year":"2015","journal-title":"Front. Oncol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1053\/j.gastro.2020.11.044","article-title":"Cadherin 11 promotes immunosuppression and extracellular matrix deposition to support growth of pancreatic tumors and resistance to gemcitabine in mice","volume":"160","author":"Peran","year":"2021","journal-title":"Gastroenterology"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1158\/0008-5472.CAN-14-1854","article-title":"Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer","volume":"75","author":"Pettazzoni","year":"2015","journal-title":"Cancer Res."},{"key":"B138","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3748\/wjg.v27.i18.2105","article-title":"Stroma-targeting strategies in pancreatic cancer: past lessons, challenges and prospects","volume":"27","author":"Polani","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Qian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12943-020-01169-7","article-title":"Metabolism of pancreatic cancer: paving the way to better anticancer strategies","volume":"19","author":"Qin","year":"2020","journal-title":"Mol. Cancer"},{"key":"B142","doi-asserted-by":"publisher","first-page":"216859","DOI":"10.1016\/j.canlet.2024.216859","article-title":"Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: challenges and opportunities","volume":"591","author":"Qin","year":"2024","journal-title":"Cancer Lett."},{"key":"B143","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1158\/0008-5472.CAN-17-3876","article-title":"Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer","volume":"78","author":"Quaranta","year":"2018","journal-title":"Cancer Res."},{"key":"B144","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","article-title":"Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer","volume":"184","author":"Raghavan","year":"2021","journal-title":"Cell"},{"key":"B145","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.molmed.2023.03.002","article-title":"Fibroblasts in pancreatic cancer: molecular and clinical perspectives","volume":"29","author":"Rebelo","year":"2023","journal-title":"Trends Mol. Med."},{"key":"B146","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.3390\/cancers14112812.T","article-title":"Cancer-associated fibroblasts confer gemcitabine resistance to pancreatic cancer cells through PTEN-targeting miRNAs in exosomes","volume":"14","author":"Richards","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/onc.2016.353","article-title":"Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells","volume":"36","author":"Richards","year":"2017","journal-title":"Oncogene"},{"key":"B148","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"B149","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B150","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMc1412266","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Ryan","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B151","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4155\/fmc-2023-0234","article-title":"Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic ductal adenocarcinoma","volume":"16","author":"Sciano","year":"2024","journal-title":"Future Med. Chem."},{"key":"B152","first-page":"243","article-title":"alpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma","volume":"34","author":"Sebens Muerkoster","year":"2009","journal-title":"Int. J. Oncol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ncb2953","article-title":"An integrin \u03b2\u2083-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition","volume":"16","author":"Seguin","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu. Rev. Pathol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1021\/acsmedchemlett.2c00369","article-title":"In the quest for potent and selective malic enzyme 3 inhibitors for the treatment of pancreatic ductal adenocarcinoma","volume":"14","author":"Sheth","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"B156","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/s0092-8674(03)00432-x","article-title":"Mechanisms of TGF-beta signaling from cell membrane to the nucleus","volume":"113","author":"Shi","year":"2003","journal-title":"Cell"},{"key":"B157","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1042\/BJ20111240","article-title":"Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression","volume":"441","author":"Shields","year":"2012","journal-title":"Biochem. J."},{"key":"B158","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","article-title":"Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer","volume":"70","author":"Shrimali","year":"2010","journal-title":"Cancer Res."},{"key":"B159","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ccell.2017.06.004","article-title":"MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer","volume":"32","author":"Shukla","year":"2017","journal-title":"Cancer Cell"},{"key":"B160","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1038\/sj.bjc.6605968","article-title":"CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy","volume":"103","author":"Singh","year":"2010","journal-title":"Br. J. Cancer"},{"key":"B162","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat. Med."},{"key":"B163","first-page":"6605","article-title":"Prevention after accidental exposure to HIV","volume":"161","author":"Skinhoj","year":"1999","journal-title":"Ugeskr. Laeger"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000062","article-title":"PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors","volume":"38","author":"Soares","year":"2015","journal-title":"J. Immunother."},{"key":"B165","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/biomedicines10020219","article-title":"Macrophage C\/EBP\u03b4 drives gemcitabine, but not 5-FU or paclitaxel, resistance of pancreatic cancer cells in a deoxycytidine-dependent manner","volume":"10","author":"Spek","year":"2022","journal-title":"Biomedicines"},{"key":"B166","doi-asserted-by":"publisher","first-page":"799","DOI":"10.32604\/or.2024.045356","article-title":"Targeting KRAS in pancreatic cancer","volume":"32","author":"Stickler","year":"2024","journal-title":"Oncol. Res."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1136\/gutjnl-2013-306271","article-title":"Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity","volume":"63","author":"Stromnes","year":"2014","journal-title":"Gut"},{"key":"B168","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ccell.2021.02.016","article-title":"Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis","volume":"39","author":"Su","year":"2021","journal-title":"Cancer Cell"},{"key":"B169","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41586-022-05169-z","article-title":"Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome","volume":"610","author":"Su","year":"2022","journal-title":"Nature"},{"key":"B170","doi-asserted-by":"publisher","first-page":"eabl7895","DOI":"10.1126\/scitranslmed.abl7895","article-title":"Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models","volume":"15","author":"Su","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"B171","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12943-020-01255-w","article-title":"The potential roles of exosomes in pancreatic cancer initiation and metastasis","volume":"19","author":"Sun","year":"2020","journal-title":"Mol. Cancer"},{"key":"B172","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B173","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1158\/0008-5472.Can-16-3062","article-title":"De novo lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancer","volume":"77","author":"Tadros","year":"2017","journal-title":"Cancer Res."},{"key":"B174","doi-asserted-by":"publisher","first-page":"964442","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"B176","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1111\/febs.14777","article-title":"Hyaluronan: molecular size-dependent signaling and biological functions in inflammation and cancer","volume":"286","author":"Tavianatou","year":"2019","journal-title":"FEBS J."},{"key":"B177","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.3892\/ol.2017.7598","article-title":"Upregulation of pyruvate kinase M2 expression by fatty acid synthase contributes to gemcitabine resistance in pancreatic cancer","volume":"15","author":"Tian","year":"2018","journal-title":"Oncol. Lett."},{"key":"B178","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1158\/1078-0432.Ccr-19-3978","article-title":"Evaluation of cyclophosphamide\/GVAX pancreas followed by listeria-mesothelin (CRS-207) with or without nivolumab in patients with pancreatic cancer","volume":"26","author":"Tsujikawa","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B179","doi-asserted-by":"publisher","first-page":"111055","DOI":"10.1016\/j.cbi.2024.111055","article-title":"Targeting PI3K\/AKT\/mTOR signaling to overcome drug resistance in cancer","volume":"396","author":"Tufail","year":"2024","journal-title":"Chem. Biol. Interact."},{"key":"B180","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.matbio.2015.01.005","article-title":"Matrix metalloproteinase interactions with collagen and elastin","author":"Van Doren","year":"2015","journal-title":"Matrix Biol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1053\/j.gastro.2017.11.280","article-title":"Reshaping the tumor stroma for treatment of pancreatic cancer","volume":"154","author":"Vennin","year":"2018","journal-title":"Gastroenterology"},{"key":"B182","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-017-0448-5","article-title":"The role of stromal cancer-associated fibroblasts in pancreatic cancer","volume":"10","author":"von Ahrens","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2018.03.008","article-title":"The immune revolution: a case for priming, not checkpoint","volume":"33","author":"Vonderheide","year":"2018","journal-title":"Cancer Cell"},{"key":"B184","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00262-013-1427-5","article-title":"CD40 immunotherapy for pancreatic cancer","volume":"62","author":"Vonderheide","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"B185","doi-asserted-by":"publisher","first-page":"9722","DOI":"10.1158\/0008-5472.CAN-05-4602","article-title":"Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells","volume":"66","author":"Wang","year":"2006","journal-title":"Cancer Res."},{"key":"B186","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/MPA.0b013e31819d7415","article-title":"Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells","volume":"38","author":"Wang","year":"2009","journal-title":"Pancreas"},{"key":"B187","doi-asserted-by":"publisher","first-page":"eadk1827","DOI":"10.1126\/sciadv.adk1827","article-title":"Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells","volume":"10","author":"Wang","year":"2024","journal-title":"Sci. Adv."},{"key":"B188","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3390\/biom11081082","article-title":"Epigenetic alterations in pancreatic cancer metastasis","volume":"11","author":"Wang","year":"2021","journal-title":"Biomolecules"},{"key":"B189","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"B190","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1021\/acs.molpharmaceut.8b00234","article-title":"A macropinocytosis-intensifying albumin domain-based scFv antibody and its conjugate directed against K-ras mutant pancreatic cancer","volume":"15","author":"Wang","year":"2018","journal-title":"Mol. Pharm."},{"key":"B191","first-page":"8211","article-title":"Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator","volume":"61","author":"Wang","year":"2001","journal-title":"Cancer Res."},{"key":"B192","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1111\/jcmm.14167","article-title":"EIF5A regulates proliferation and chemoresistance in pancreatic cancer through the sHH signalling pathway","volume":"23","author":"Wang","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"B193","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/1078-0432.Ccr-23-2098","article-title":"A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer","volume":"30","author":"Wei","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B194","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41419-021-03574-2","article-title":"Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-\u03b21\/SMAD2\/3 pathway and ABCC1 transactivation","volume":"12","author":"Wei","year":"2021","journal-title":"Cell Death Dis."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41419-018-1104-x","article-title":"Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1\/SATB-1 pathway in pancreatic cancer","volume":"9","author":"Wei","year":"2018","journal-title":"Cell Death Dis."},{"key":"B196","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41568-021-00427-0","article-title":"Towards targeting of shared mechanisms of cancer metastasis and therapy resistance","volume":"22","author":"Weiss","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"B197","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/cancers10090316","article-title":"The extracellular matrix and pancreatic cancer: a complex relationship","volume":"10","author":"Weniger","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B198","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1634\/theoncologist.2014-0086","article-title":"Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma","volume":"19","author":"Wolpin","year":"2014","journal-title":"Oncologist"},{"key":"B199","doi-asserted-by":"publisher","first-page":"e1319044","DOI":"10.1080\/2162402X.2017.1319044","article-title":"Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer","volume":"6","author":"Xiao","year":"2017","journal-title":"Oncoimmunology"},{"key":"B200","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.canlet.2013.01.002","article-title":"ABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistance","volume":"333","author":"Xu","year":"2013","journal-title":"Cancer Lett."},{"key":"B201","doi-asserted-by":"publisher","first-page":"101035","DOI":"10.1016\/j.gendis.2023.05.022","article-title":"Regulation of AMPK activation by extracellular matrix stiffness in pancreatic cancer","volume":"11","author":"Xu","year":"2024","journal-title":"Genes Dis."},{"key":"B202","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3892\/ijo.2012.1333","article-title":"Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis","volume":"40","author":"Yamahatsu","year":"2012","journal-title":"Int. J. Oncol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"key":"B204","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1158\/2159-8290.Cd-14-0362","article-title":"Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations","volume":"4","author":"Yang","year":"2014","journal-title":"Cancer Discov."},{"key":"B205","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.bbrc.2018.09.061","article-title":"Integrin \u03b21 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110\u03b2 signaling","volume":"505","author":"Yang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B206","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1101\/gad.2016111","article-title":"Pancreatic cancers require autophagy for tumor growth","volume":"25","author":"Yang","year":"2011","journal-title":"Genes Dev."},{"key":"B207","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-019-1062-1","article-title":"Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer","volume":"568","author":"Yao","year":"2019","journal-title":"Nature"},{"key":"B208","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.3390\/cancers13153667","article-title":"DC-derived exosomes for cancer immunotherapy","volume":"13","author":"Yao","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B209","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1158\/1535-7163.Mct-20-1103","article-title":"Radiosensitizing pancreatic cancer via effective autophagy inhibition","volume":"21","author":"Yazal","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"B210","doi-asserted-by":"publisher","first-page":"1244752","DOI":"10.3389\/fphar.2023.1244752","article-title":"Integrated multi-omics identified the novel intratumor microbiome-derived subtypes and signature to predict the outcome, tumor microenvironment heterogeneity, and immunotherapy response for pancreatic cancer patients","volume":"14","author":"Zhang","year":"","journal-title":"Front. Pharmacol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"9718","DOI":"10.18632\/aging.205044","article-title":"Integrated single-cell and bulk RNA sequencing revealed the molecular characteristics and prognostic roles of neutrophils in pancreatic cancer","volume":"15","author":"Zhang","year":"","journal-title":"Aging (Albany NY)"},{"key":"B212","doi-asserted-by":"publisher","first-page":"112620","DOI":"10.1016\/j.celrep.2023.112620","article-title":"Multi-omics analysis reveals the chemoresistance mechanism of proliferating tissue-resident macrophages in PDAC via metabolic adaptation","volume":"42","author":"Zhang","year":"","journal-title":"Cell Rep."},{"key":"B213","doi-asserted-by":"publisher","first-page":"188583","DOI":"10.1016\/j.bbcan.2021.188583","article-title":"Matrix stiffness and its influence on pancreatic diseases","volume":"1876","author":"Zhang","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B214","doi-asserted-by":"publisher","first-page":"1104860","DOI":"10.3389\/fimmu.2023.1104860","article-title":"Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer","volume":"14","author":"Zhang","year":"","journal-title":"Front. Immunol."},{"key":"B215","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41419-023-06060-z","article-title":"Cancer-associated fibroblasts: tumor defenders in radiation therapy","volume":"14","author":"Zhang","year":"","journal-title":"Cell Death Dis."},{"key":"B216","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/cancers15010062","article-title":"The effect of oxidative phosphorylation on cancer drug resistance","volume":"15","author":"Zhao","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B217","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1038\/s41467-020-20108-0","article-title":"Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways","volume":"11","author":"Zhong","year":"2020","journal-title":"Nat. Commun."},{"key":"B218","doi-asserted-by":"publisher","first-page":"216457","DOI":"10.1016\/j.canlet.2023.216457","article-title":"A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance","volume":"578","author":"Zhou","year":"","journal-title":"Cancer Lett."},{"key":"B219","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13046-023-02671-8","article-title":"Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo\/YAP1\/c-Jun axis","volume":"42","author":"Zhou","year":"","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B220","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.freeradbiomed.2024.01.003","article-title":"Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells","volume":"212","author":"Zhou","year":"2024","journal-title":"Free Radic. Biol. Med."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1462808\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T06:13:12Z","timestamp":1736748792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1462808\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":220,"alternative-id":["10.3389\/fcell.2024.1462808"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2024.1462808","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"article-number":"1462808"}}